目錄:北京索萊寶科技有限公司>>抗體>>Polyclonal Antibody>> K106720PAnti-P27 Polyclonal Antibody
| 供貨周期 | 現貨 | 規格 | 50ul/100ul |
|---|---|---|---|
| 貨號 | K106720P | 應用領域 | 醫療衛生,環保,化工,生物產業,農業 |
| 主要用途 | IHC |
Anti-P27 Polyclonal Antibody
| 英文名稱 | Anti-P27 Polyclonal Antibody |
|---|---|
| 宿主 | Rabbit |
| 別名 | CDKN1B;CDKN4;KIP1;MEN1B;MEN4;P27;KIP1;P27KIP1 |
| 應用 | IHC |
| 稀釋比例 | IHC 1:50-200. |
| 交叉反應 | Human |
| 蛋白分子量 | 22kDa |
| Gene ID | 1027 |
| 保存 | Store at -20°C. Avoid freeze / thaw cycles. |
| 儲存液 | Buffer: PBS with 0.03% Proclin300, 50% glycerol, pH7.3. |
| 純化方法 | Affinity purification |
| 亞型 | IgG |
| 免疫原 | Recombinant protein of human P27 |
| 性狀 | 液體 |
| Public Immunogen Range | Recombinant protein of human P27 |
| Subcellular Locations | Nucleus |
| Swiss Prot | P46527 |
| 克隆類型 | Polyclonal Antibody |
| 背景資料 | This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4) |
15
化工儀器網